Med­i­cines Co, Al­ny­lam gen­er­ate pos­i­tive buzz with ev­i­dence of a durable, 6-month LDL re­sponse to PC­SK9 ri­val

The Med­i­cines Com­pa­ny $MD­CO and its part­ner Al­ny­lam $AL­NY post­ed an im­pres­sive set of 6-month re­sults for the first batch of pa­tients to reach the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.